We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

25 hedge funds and large institutions have $231M invested in Milestone Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

9% more funds holding

Funds holding: 23 → 25 (+2)

5.43% more ownership

Funds ownership: 53.37% → 58.8% (+5.4%)

4% less capital invested

Capital invested by funds: $240M → $231M (-$9.08M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
25
Holders Change
+2
Holders Change %
+8.7%
% of All Funds
0.49%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
4
Increased
8
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
TCM
Tekla Capital Management
Massachusetts
+$12.4M
2
RI
RTW Investments
New York
+$7.72M
3
O
OrbiMed
New York
+$6.44M
4
ACP
Acuta Capital Partners
California
+$2.46M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.77M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$4.97M
2
NHAS
Novo Holdings A/S
Denmark
-$4.25M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$250K
4
OAM
Oxford Asset Management
United Kingdom
-$113K
5
Invesco
Invesco
Georgia
-$45.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$63.4M +$7.72M +436,408 +12%
NHAS
2
Novo Holdings A/S
Denmark
$39M -$4.25M -240,000 -9%
VMI
3
VHCP Management III
New York
$33.1M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$20.6M -$250K -14,139 -1%
BC
5
Boxer Capital
California
$17.6M – – –
TCM
6
Tekla Capital Management
Massachusetts
$12M +$12.4M +699,713 +1,491%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$9.61M +$1.77M +100,000 +20%
ACP
8
Acuta Capital Partners
California
$8.14M +$2.46M +139,000 +38%
O
9
OrbiMed
New York
$5.83M +$6.44M +364,206 New
Invesco
10
Invesco
Georgia
$5.16M -$45.4K -2,567 -0.8%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$3.84M – – –
GTC
12
Ghost Tree Capital
New York
$3.76M – – –
ZP
13
Zimmer Partners
New York
$2.56M – – –
VMI
14
VHCP Management II
New York
$2.38M – – –
Morgan Stanley
15
Morgan Stanley
New York
$749K +$815K +46,071 +6,582%
PM
16
Prosight Management
Texas
$616K +$681K +38,481 New
TD Asset Management
17
TD Asset Management
Ontario, Canada
$581K – – –
PCM
18
Pentwater Capital Management
Florida
$512K +$124K +7,000 +28%
Millennium Management
19
Millennium Management
New York
$472K +$102K +5,790 +24%
FDCDDQ
20
Federation des caisses Desjardins du Quebec
Quebec, Canada
$368K +$402K +22,715 +8,113%
OAM
21
Oxford Asset Management
United Kingdom
$316K -$113K -6,382 -24%
Barclays
22
Barclays
United Kingdom
$14K +$15.9K +900 New
CFGS
23
Concourse Financial Group Securities
Alabama
$4K +$4.33K +245 New
TRCT
24
Tower Research Capital (TRC)
New York
$2K -$124 -7 -5%
WAP
25
Wealthcare Advisory Partners
Pennsylvania
$1K – – –
1
2

MIST Hedge Fund Activity: Q4 2019 in Review

25 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2019, worth a combined $231M — down 3.8% from $240M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MIST positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Tekla Capital Management, adding an estimated $12.4M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.97M sold.

  • 25 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2019, up from 23 in Q3 2019.
  • Funds reported $231M of Milestone Pharmaceuticals stock for Q4 2019, down 3.8% quarter-over-quarter.
  • 4 funds opened new Milestone Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of +2 holders.
  • The largest Milestone Pharmaceuticals buyer in Q4 2019 was Tekla Capital Management, an estimated $12.4M added.
  • The largest Milestone Pharmaceuticals seller in Q4 2019 was Baker Bros. Advisors, an estimated $4.97M sold.

Based on aggregated 13F filings for Q4 2019.